ZA200400137B - Inhibition of apoptosis process and improvement of cell performance - Google Patents

Inhibition of apoptosis process and improvement of cell performance

Info

Publication number
ZA200400137B
ZA200400137B ZA200400137A ZA200400137A ZA200400137B ZA 200400137 B ZA200400137 B ZA 200400137B ZA 200400137 A ZA200400137 A ZA 200400137A ZA 200400137 A ZA200400137 A ZA 200400137A ZA 200400137 B ZA200400137 B ZA 200400137B
Authority
ZA
South Africa
Prior art keywords
cell
inhibition
improvement
cell performance
related product
Prior art date
Application number
ZA200400137A
Other languages
English (en)
Inventor
Mitchell Reff
Figueroa Bruno Jr
Marie Hardwick
Michael J Betenbaugh
Eric Ailor
Original Assignee
Biogen Idec Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Univ Johns Hopkins filed Critical Biogen Idec Inc
Publication of ZA200400137B publication Critical patent/ZA200400137B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA200400137A 2001-07-10 2004-01-08 Inhibition of apoptosis process and improvement of cell performance ZA200400137B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30381301P 2001-07-10 2001-07-10

Publications (1)

Publication Number Publication Date
ZA200400137B true ZA200400137B (en) 2006-06-28

Family

ID=23173824

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200508985A ZA200508985B (en) 2001-07-10 2002-07-10 Inhibition of apotosis process and improvement of cell performance
ZA200400137A ZA200400137B (en) 2001-07-10 2004-01-08 Inhibition of apoptosis process and improvement of cell performance

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA200508985A ZA200508985B (en) 2001-07-10 2002-07-10 Inhibition of apotosis process and improvement of cell performance

Country Status (13)

Country Link
US (1) US7604989B2 (xx)
EP (1) EP1414948B1 (xx)
JP (2) JP4435563B2 (xx)
KR (1) KR20040044433A (xx)
CN (1) CN1526011A (xx)
AT (1) ATE443131T1 (xx)
AU (1) AU2002315534B2 (xx)
CA (1) CA2452005C (xx)
DE (1) DE60233738D1 (xx)
MX (1) MXPA04000281A (xx)
NO (1) NO20040101L (xx)
WO (1) WO2003006607A2 (xx)
ZA (2) ZA200508985B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
KR100454016B1 (ko) * 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
EP1587934B1 (en) 2003-02-01 2010-06-23 Millipore Corporation Improved genetic elements providing high levels of expression
WO2005040364A1 (ja) * 2003-10-24 2005-05-06 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 新規なタンパク質高産生組換え動物細胞、その作製方法及びそれを用いたタンパク質を大量産生する方法
EP1702071B1 (en) * 2003-12-31 2012-02-22 Kalobios Inc. Transactivation system for mammalian cells
AU2005333513B2 (en) * 2004-07-23 2011-06-02 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
SG163592A1 (en) * 2004-07-23 2010-08-30 Immunomedics Inc Methods and compositions for increasing longevity and protein yield from a cell culture
US7608425B2 (en) * 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
GB0509965D0 (en) 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
CA2649148C (en) * 2006-04-13 2016-08-23 Chugai Seiyaku Kabushiki Kaisha Taurine transporter gene
US20100167396A1 (en) * 2006-04-21 2010-07-01 Bayer Healthcare Llc Application of Anti-Apoptotic Gene Expression in Mammalian Cells for Perfusion Culture
CN101802170A (zh) * 2007-01-08 2010-08-11 米利波尔公司 在存在降低水平的一或多种污染物的条件下制备重组蛋白的细胞培养方法
DK2300600T3 (en) 2008-06-13 2015-10-12 Janssen Biotech Inc Approaches for improving the viability and productivity in a cell culture
US20130065312A1 (en) * 2009-11-03 2013-03-14 The Johns Hopkins University Method and composition for generating programmed cell death resistant algal cells
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
KR102711314B1 (ko) 2018-06-28 2024-09-27 삼성디스플레이 주식회사 유기 발광 표시 장치

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
CA2149326C (en) 1992-11-13 2007-04-17 Mitchell E. Reff Fully impaired consensus kozak sequences for mammalian expression
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US5897992A (en) 1996-09-27 1999-04-27 Cold Spring Harbor Laboratory Cell-free assay using oncogene-induced apoptosis in drug-resistant cells
US6011138A (en) 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
ES2315016T3 (es) 1998-08-07 2009-03-16 Immunex Corporation Moleculas llamadas b7l-1.
CA2363621A1 (en) 1999-02-26 2000-08-31 The Johns Hopkins University A novel inhibitor of programmed cell death
US6140118A (en) 1999-08-11 2000-10-31 Wisconsin Alumni Research Foundation Avian blastodermal cell lines
PT1650307E (pt) 1999-09-27 2010-10-21 Genentech Inc Métodos para preparação de proteínas recombinantes utilizando inibidores de apoptose
ES2257336T3 (es) * 1999-11-12 2006-08-01 MERCK & CO., INC. Derivados de diaril piperidil pirrol como agentes antiprotozoarios.
KR100454016B1 (ko) 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
EP1348758A1 (en) 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Host cells having improved cell survival properties and methods to generate such cells

Also Published As

Publication number Publication date
EP1414948B1 (en) 2009-09-16
AU2002315534B2 (en) 2008-05-22
CA2452005A1 (en) 2003-01-23
EP1414948A2 (en) 2004-05-06
MXPA04000281A (es) 2004-07-23
JP2009118851A (ja) 2009-06-04
NO20040101L (no) 2004-03-09
ATE443131T1 (de) 2009-10-15
JP4435563B2 (ja) 2010-03-17
WO2003006607A2 (en) 2003-01-23
WO2003006607A9 (en) 2003-04-10
WO2003006607A3 (en) 2003-07-31
DE60233738D1 (de) 2009-10-29
JP2005525782A (ja) 2005-09-02
CN1526011A (zh) 2004-09-01
KR20040044433A (ko) 2004-05-28
ZA200508985B (en) 2006-07-26
CA2452005C (en) 2011-03-15
EP1414948A4 (en) 2006-06-21
US7604989B2 (en) 2009-10-20
US20030064510A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
ZA200400137B (en) Inhibition of apoptosis process and improvement of cell performance
EP1444329A4 (en) STEM CELLS CONVERTING TO CARDIOMYOCYTES WITH SPONTANEOUS BEATS
SG170082A1 (en) Methods for regulating inflammatory mediators and peptides useful therein
YU40402A (xx) 4-pirimidinil-n-acil-l-fenilalanini
EP1483281A4 (en) METHOD FOR THE PRODUCTION OF INTERFERING RNA MOLECULES IN MAMMALIAN CELLS AND THERAPEUTIC APPLICATIONS OF SUCH MOLECULES
PL1948789T3 (pl) Sposób wytwarzania ciągłych ludzkich linii komórkowych
PL368033A1 (en) Method of continuously casting electrical steel strip with controlled spray cooling
WO1996035774A3 (en) Angiostatin fragments and aggregate angiostatin and methods of use
HK1041476A1 (en) Cell adhesion-inhibiting antiinflammatory and immunesuppressive compounds
AU2002339299A1 (en) In vitro production of haploid germ cells
IL124015A0 (en) Pharmaceutical compositions comprising a protein
AU2001275659A1 (en) Extracts from sophora species, method for producing the same and their use
PL335640A1 (en) Deep-frozen article of food
ATE349914T1 (de) Olivenpulver
WO2007124106A3 (en) Application of antl-apoptotic genes in mammalian cells for perfusion culture.
MXPA03007713A (es) Metodos para elaborar un oxido de metal de niobio.
HUP0500029A3 (en) Production process of recombinant placental growth factor
WO2003066814A3 (en) Peptide-dependent upregulation of telomerase expression
NZ515531A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
IL184081A0 (en) Synthesis using peptide intermediate fragments iii
WO2003082900A3 (en) Self-assembling-peptide-based structures and processes for controlling the self-assembly of such structures
YU72603A (sh) Proizvodnja i izdvajanje indolokarbazol glikozida
ES2032354B1 (es) Procedimiento para la fabricacion de papillas a base de cereales y papillas obtenidas con dicho procedimiento.
WO2002068668A3 (en) Compositions and methods for production cell culture
WO1998034602A3 (en) Mediation of cytokines by melanin